Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung cancer, 2012 - Elsevier
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
被引用次数：91 相关文章

[引用][C] Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung Cancer, 2012 - cir.nii.ac.jp
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to
gefitinib: A single-arm, open-label, phase II study | CiNii Research CiNii 国立情報学研究所 学術 …

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung Cancer, 2012 - lungcancerjournal.info
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …

[引用][C] Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study

IJ OH, HJ BAN, KS KIM, YC KIM - Lung cancer, 2012 - pascal-francis.inist.fr
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to
gefitinib: A single-arm, open-label, phase II study CNRS Inist Pascal-Francis CNRS Pascal and …

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung Cancer (Amsterdam …, 2012 - europepmc.org
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung Cancer, 2012 - infona.pl
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study

IJ Oh, HJ Ban, KS Kim, YC Kim - Lung cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …